SCHEMBL12200069

SCHEMBL12200069

CC(C)(C)OC(=O)C1CCC(Oc2ccc(C(=O)NC3CCN(Cc4ccccc4)CC3)cc2Cl)CC1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 2/20 0.58
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
SLC6A12 P48065 3/20 0.53
SLC6A13 Q9NSD5 2/20 0.53
DRD4 P21917 1/20 0.53
MAOB P27338 1/20 0.52
MCHR1 Q99705 2/20 0.52
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TMEM97 Q5BJF2 2/20 0.50
SIGMAR1 Q99720 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12200071 0.91 KMT2A (0.55) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL12200070 0.90 UTS2R (0.59) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL2391052 0.88 UTS2R (0.60) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL2389013 0.88 UTS2R (0.71) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL2389289 0.86 UTS2R (0.62) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL2390533 0.85 MEN1 (0.72) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL2387749 0.84 UTS2R (0.70) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL2387583 0.83 UTS2R (0.68) UTS2RSLC6A12SLC6A13DRD4CYP2D6
SCHEMBL12226765 0.83 UTS2R (0.69) UTS2RKMT2AMEN1SLC6A12SLC6A13
SCHEMBL14146933 0.83 UTS2R (0.62) UTS2RKMT2AMEN1SLC6A12SLC6A13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110245222-A1 Methods for Using Carboxamide, Sulfonamide and Amine Compounds RIGEL PHARMACEUTICALS, INC. (US) 2011-10-06 US disclosed
US-20110245222-A1 Methods for Using Carboxamide, Sulfonamide and Amine Compounds RIGEL PHARMACEUTICALS, INC. (US) 2011-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245222-A1 Methods for Using Carboxamide, Sulfonamide and Amine Compounds CS, SHMT2, GOT2 UTS2R 1156/4885KMT2A 634/4885MEN1 4748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.